Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...2829303132333435363738...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION? () -  May 24, 2022 - Abstract #EULAR2022EULAR_4060;    
    Our study did not reveal any significant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral antiosteoporotic therapy. We conclude that parenteral antiosteoporotic drugs (Zoledronic acid, Ibandronic acid, or Denosumab) do not have an influence on COVID-19 frequency and severity and can be recommended for the continuation of treatment of patients with osteoporosis.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME () -  May 24, 2022 - Abstract #EULAR2022EULAR_2863;    
    Clinical efficacy of treatment with ROMO for 12months and DMB for 6months for RA-OP was extremely effective and has the high potential to be an important option in the treatment of RA-OP. A lower probability of refracture was observed in patients who received sequential treatment with teriparatide followed by denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    CHARACTERISTICS OF PATIENTS REFERRED FOR FIRST BONE DENSITOMETRY TO A RHEUMATOLOGY FLS, WITH NORMAL RESULTS IN THE LUMBAR SPINE () -  May 24, 2022 - Abstract #EULAR2022EULAR_2862;    
    Among the patients referred to BMD, although the result of lumbar spine is normal, 17% have suffered an OP fracture, presenting this group: 1) Older age, 2) Osteopenia in hip BMD 50%, with high risk of fracture due to FRAX and they followed treatment for OP, especially oral bisphosphonates. 3) It is advisable to simultaneously perform BMD at the lumbar and hip levels, especially in older subjects
  • ||||||||||  HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
    Trial completion date, Trial primary completion date:  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia (clinicaltrials.gov) -  May 23, 2022   
    P3,  N=430, Recruiting, 
    However, we found no dose-response relationship by looking at exercise frequency. Trial completion date: Dec 2024 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Evenity (romosozumab) / Astellas, Amgen, UCB
    Clinical, Journal:  Romosozumab and antiresorptive treatment: the importance of treatment sequence. (Pubmed Central) -  May 19, 2022   
    In this study, larger mean BMD increases and greater BMD responder rates were achieved when romosozumab was used before, versus after, an antiresorptive agent. Since BMD on treatment is a strong surrogate for bone strength and fracture risk, this analysis supports the thesis that initial treatment with romosozumab followed by an antiresorptive will result in greater efficacy versus the reverse sequence.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Gastric carcinoma's primary presentation as multiple cutaneous nodules throughout the body. (Pubmed Central) -  May 18, 2022   
    An esophagogastroduodenoscopy was performed and a poorly differentiated signet-ring type invasive adenocarcinoma at the lesser curvature of the stomach was found. As the cancer had already metastasized to the skin and bones, the patient was started on chemotherapy with an oxaliplatin-based regimen and denosumab for the bone metastases, with resultant objective response and diagnostic control for greater than one year to the present date.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years. (Pubmed Central) -  May 18, 2022   
    Microhardness in cortical and cancellous compartments was significantly lower at 5?years of DMAb vs 2/3?years and was not different from years 5 to 10. The lower microhardness at years 5 and 10 is likely the result of maturation of the organic matrix in a persistently low state of bone remodeling over 5 and 10?years.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Safety of denosumab in patients with chronic kidney disease. (Pubmed Central) -  May 17, 2022   
    There was no deterioration in renal function while using denosumab. In this regard, close monitoring of this group of patients is essential, as well as medication adjustments.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Seizures Associated With Bone Density Conservation Agents. (Pubmed Central) -  May 17, 2022   
    The correction of underlying conditions and electrolyte disturbances should be addressed before initiating a BDCA. Further studies are needed to better explore the relationship between BDCA and seizures.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal, HEOR, Real-world evidence:  Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence. (Pubmed Central) -  May 15, 2022   
    Most GCTB patients with localized disease can be successfully treated with surgical curettage, and the role of denosumab in preoperative therapy in this patient population remains unclear. (4) However, patients with primary unresectable lesions or metastases may experience long-term clinical and radiological remission and pain control with denosumab treatment, and in this clinical situation, denosumab is currently the treatment of choice.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis. (Pubmed Central) -  May 15, 2022   
    Through the inhibition of the RANK-RANKL system, denosumab is the only antiresorptive drug currently available that exhibits both a systemic anti-osteoporotic activity and a disease-modifying effect when combined with conventional synthetic or biologic disease-modifying anti-rheumatic drugs (DMARDs). Thus, the combination of DMARD and anti-RANKL therapy could be beneficial in the prevention of fragility fractures and structural damage in the subset of RA patients at risk of radiographic progression, as in the presence of ACPAs.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ). (Pubmed Central) -  May 14, 2022   
    The initial reports associated MRONJ to bisphosphonates and denosumab, medications that work as bone-modifying agents...This mini review focused on the cancer patient. It updates the dental clinician on the recent scientific literature about MRONJ and provides information on how to diagnose and manage patients being treated with these medications, suggests protocols to prevent the development of MRONJ, and present ways to manage those patients who develop the oral complication.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA () -  May 13, 2022 - Abstract #EHA2022EHA_1967;    
    Conclusion Denosumab is a new weapon in the prevention and treatment of bone disease. Its use is simpler (subcutaneous route), of similar efficacy and also more manageable depending on the renal insufficiency with a significant improvement in the quality of life
  • ||||||||||  HLX14 (denosumab biosimilar) / Fosun Pharma, Organon
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia (clinicaltrials.gov) -  May 11, 2022   
    P1,  N=228, Recruiting, 
    No abstract available Not yet recruiting --> Recruiting | N=24 --> 228 | Trial completion date: Aug 2021 --> Aug 2023 | Trial primary completion date: Dec 2020 --> Jul 2023
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Current management of giant-cell tumor of bone in the denosumab era. (Pubmed Central) -  May 10, 2022   
    Therefore, controversy regarding the treatment of giant-cell tumor of bone is ongoing. Here, this review elucidates the management of giant-cell tumor of bone, especially with the local adjuvant and neoadjuvant use of denosumab, and presents the current, evidence-based treatment for giant-cell tumor of bone.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    New trial:  Post-fracture Medication and Mortality (clinicaltrials.gov) -  May 8, 2022   
    P=N/A,  N=216155, Completed, 
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Xpovio (selinexor) / Karyopharm, Menarini
    Journal:  Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision) (Pubmed Central) -  May 7, 2022   
    Overwhelmingly, autologous stem cell transplantation (ASCT) still plays an irreplaceable role in MM treatment. In the supportive treatment section, the administration of thromboprophylaxis and denosumab were added.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Clinical, Journal:  The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids. (Pubmed Central) -  May 6, 2022   
    In the supportive treatment section, the administration of thromboprophylaxis and denosumab were added. In this analysis of short-term denosumab use in subjects with RA receiving GCs, denosumab discontinuation resulted in a gradual increase in bone turnover, which was associated with a return to baseline LS and TH BMD.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
    Challenges in Conducting Pragmatic Care Strategy Studies in Osteoporosis: Patient Perceptions (Poster View 8) -  May 6, 2022 - Abstract #EULAR2022EULAR_2544;    
    We identified several potential modifiable barriers to clinical trial recruitment. Patient perceptions collected from this pilot will inform enrollment strategies, which can be incorporated early when planning direct-to-patient pragmatic osteoporosis studies to achieve recruitment goals.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
    Clinical, Review, Journal:  The effect of osteoporosis treatment on bone mass. (Pubmed Central) -  May 6, 2022   
    After discontinuation of these antibodies, bone mineral density quickly returns to baseline and in the case of denosumab, discontinuation can not only induce rebound bone loss, but also the occurrence of vertebral fractures. Therefore, sequential antiresorptive therapy to maintain bone mass gains and anti-fracture efficacy is of utmost importance and will also be discussed in this review.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Review, Journal:  Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature. (Pubmed Central) -  May 6, 2022   
    In this review, we outline the effects of denosumab withdrawal on bone turnover markers, BMD, histomorphometry, and fracture risk. We provide an update on recent clinical trials that sought to answer how clinicians can transition away from denosumab safely with follow-on therapy to mitigate bone loss and summarise the recommendations of various international guidelines.